Is Profound Medical Corp. (NASDAQ:PROF) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Profound Medical Corp. at current levels.
TULSA-PRO is shifting from adoption story to reimbursement story, and 2027's CPT Category I code is the pivot the market keeps discounting.
Where PROF is headed
Profound Medical exits 2027 with something it has never had: a durable, hospital-friendly reimbursement pathway for TULSA-PRO in the United States. The CPT Category I code effective January 2027 is the difference between a device that urologists like and a device that hospital CFOs will actually let them buy. That single procedural change reshapes the installed base math. Roughly 90 active US sites today become the seed layer for a network that should approach 200 by end of 2027 if the reimbursement transition lands as CMS pricing suggests. Revenue growth accelerates from the low teens run-rate into the 40 to 60 percent range as recurring disposable revenue per site compounds on top of new capital placements.
Read the full Compass Direction on PROF
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $6.80).
See the full PROF analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Profound Medical Corp. (NASDAQ:PROF) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Profound Medical Corp. at current levels. TULSA-PRO is shifting from adoption story to reimbursement story, and 2027's CPT Category I code is the pivot the market keeps discounting.
What is PROF's Compass Score?
Profound Medical Corp. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for PROF?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PROF page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.